The Shareholders Foundation announces that a deadline is coming up on April 17, 2017 in the lawsuit filed for certain investors in NASDAQ:ANTH shares against Anthera Pharmaceuticals Inc over alleged securities laws violations.
Investors who purchased shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) have certain options and there are strict and short deadlines running. Deadline: April 17, 2017. NASDAQ:ANTH stockholders should contact the Shareholders Foundation at email@example.com or call +1(858) 779 – 1554.
The plaintiff claims that Anthera Pharmaceuticals Inc made materially false and/or misleading statements concerning the potential efficacy and success of its Solution Study and CHABLIS-SC1 clinical trials, as the Company failed to disclose that patients were not improving in the CHABLIS-SC1 clinical trial, and that there were dosing problems inherent in the Solution Study design that created challenges to obtaining responses.
Hayward, CA based Anthera Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune disease. Shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) reached in 2015 as high as $10.91 per share.
On November 10, 2016, Anthera Pharmaceuticals Inc announced that “the CHABLIS-SC1 clinical trial with blisibimod for the treatment of systemic lupus erythematosus (SLE) failed to meet its primary endpoint based upon the SLE Responder Index-6 (SRI-6) at 52 weeks.”
On December 27, 2016, Anthera Pharmaceuticals Inc announced that its SOLUTION Phase 3 Study for liprotamase also failed to meet its primary endpoint. The Company announced it would conduct a new study of liprotamase.
Shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) declined to as low as $0.64 per share on December 30, 2016.
Those who purchased NASDAQ:ANTH shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego